Skip to main content
. 2015 Feb 11;18(2):92–103. doi: 10.1177/1098612X15572416

Table 1.

Clinical and scintigraphic characteristics of 2096 hyperthyroid cats, divided into five groups based on disease duration

Time from diagnosis All cats Group 1 (⩽1 year) Group 2 (>1–2 years) Group 3 (>2–3 years) Group 4 (>3–4 years) Group 5 (>4–6.1 years)
Number of cats (%) 2096 (100.0) 1773 (84.5) 169 (8.1) 88 (4.2) 35 (1.7) 31 (1.5)
Methimazole (%) 996 (47.5) 673 (38.0) 169 (100.0) 88 (100.0) 35 (100.0) 31 (100.0)
Tumor pattern (%)
 Unilateral 665 (31.7) 599 (33.8) 39 (23.1) 18 (20.5) 6 (17.1) 3 (9.7)
 Bilateral 1317 (62.8) 1107 (62.4) 113 (66.9) 59 (67.0) 20 (57.2) 18 (58.0)
 Multifocal 81 (3.9) 48 (2.7) 13 (7.7) 8 (9.1) 5 (14.3) 7 (22.6)
 Unclassified 33 (1.6) 19 (1.1) 4 (2.4) 3 (3.4) 4 (11.4) 3 (9.7)
Tumor location (%)
 Cervical 2057 (98.1) 1744 (98.4) 166 (98.2) 85 (96.6) 33 (94.3) 29 (93.4)
 Thoracic inlet 282 (13.5) 162 (9.1) 48 (28.4) 33 (37.5) 22 (62.9) 17 (54.8)
 Thorax 115 (5.5) 63 (3.6) 17 (10.1) 15 (17.0) 10 (28.6) 10 (32.2)
Tumor size (%)
 Small 1135 (54.2) 1101 (62.1) 26 (15.4) 7 (8.0) 1 (2.9) 0 (0)
 Medium 682 (32.5) 581 (32.8) 69 (40.8) 25 (28.4) 3 (8.6) 4 (12.9)
 Large 230 (11.0) 82 (4.6) 64 (37.9) 47 (53.4) 21 (60.0) 16 (51.6)
 Huge 49 (2.3) 9 (0.5) 10 (5.9) 9 (10.2) 10 (28.6) 11 (35.5)
Ectopic (%)
 All ectopic locations 79 (3.8) 58 (3.3) 11 (6.5) 5 (5.7) 3 (8.6) 2 (6.4)
 Sublingual 8 (0.4) 7 (0.4) 1 (0.6) 0 (0) 0 (0) 0 (0)
 Cervical 6 (0.3) 5 (0.3) 1 (0.6) 0 (0) 0 (0) 0 (0)
 Mediastinal 64 (3.1) 46 (2.6) 8 (4.7) 5 (5.7) 3 (8.6) 2 (6.4)
 Both sublingual and mediastinal 1 (0.05) 1 (0.1) 0 (0) 0 (0) 0 (0) 0 (0)
Suspected carcinoma (%)
 All suspected cases 35 (1.7) 9 (0.5) 6 (3.6) 6 (6.8) 6 (17.1) 8 (25.8)
 SHIM-RAD subgroup* 30 (1.4) 7 (0.4) 6 (3.6) 6 (6.8) 5 (14.3) 6 (19.3)
*

SHIM-RAD = subgroup of cats with thyroid tumors that have the following five features: (1) severe hyperthyroidism (serum thyroxine >300 nmol/l); (2) huge tumors; (3) intrathoracic tumor location; (4) multifocal distribution of radionuclide uptake; and (5) refractory to treatment with antithyroid drugs